- Home
- JANX vs ABSI Comparison
JANX vs ABSI Comparison
Compare JANX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | ABSI |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 840.4M | 997.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JANX | ABSI |
|---|---|---|
| Price | $14.64 | $10.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $47.00 | $6.96 |
| AVG Volume (30 Days) | 845.1K | ★ 5.4M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.12 | $2.24 |
| 52 Week High | $35.34 | $8.57 |
Technical Indicators
Market Signals| Indicator | JANX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 71.48 |
| Support Level | $13.13 | $2.76 |
| Resistance Level | $15.49 | N/A |
| Average True Range (ATR) | 0.57 | 0.92 |
| MACD | 0.15 | 0.19 |
| Stochastic Oscillator | 84.78 | 79.43 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.